Performance Evaluation of an Ultra-Sensitive Assay for NSCLC Biomarker Testing

Posters Jun 23, 2025
Oncology
|
PCR

June 23, 2025

Nathalie Bernard¹, Magdalena Stolarek-Januszkiewicz², Christina Xyrafaki², Ana-Luisa Silva², Justyna Mordaka², Sara Diels¹, Dirk Goossens¹, Lien Heyrman¹, Bart Tegenbos¹, Jurgen Del Favero

Performance Evaluation of an Ultra-Sensitive Assay for NSCLC Biomarker Testing

Featured Resources

See All Experts' Insights
Header 1024x341 Blog
Jun 30, 2026

CAR Kinetics in Autoimmune Studies: Expert Insights on Designing Effective Monitoring Strategies | CellCarta
Genomics Assay List Brochure
Apr 15, 2026

Genomic Assay List
Picture3 Posters
Mar 3, 2026

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
See All Experts' Insights

One global CRO for your whole therapeutic development journey

CellCarta has the multi-modal capabilities, scientific depth, and harmonized global footprint needed to advance even the most complex programs in precision medicine.

Talk to our Team
cta banner